The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 16, 2024

Filed:

Aug. 21, 2019
Applicants:

Daiichi Sankyo Co., Ltd., Tokyo, JP;

Daiichi Sankyo Europe Gmbh, Munich, DE;

Kinki University, Osaka, JP;

Amgen, Inc., Thousand Oaks, CA (US);

Inventors:

Matthias Schneider, Neufarn, DE;

Sabine Blum, Munich, DE;

Renee Jeanne Mendell-Harary, Skillman, NJ (US);

Daniel J. Freeman, Holmdel, NJ (US);

Robert Allen Beckman, Blue Bell, PA (US);

Xiaoping Jin, Hillsborough, NJ (US);

Kimio Yonesaka, Osakasayama, JP;

Kazuhiko Nakagawa, Osakasayama, JP;

Assignees:

Daiichi Sankyo Co., Ltd., Tokyo, JP;

Daiichi Sankyo Europe GmbH, Munich, DE;

Kinki University, Osaka, JP;

Amgen, Inc., Thousand Oaks, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); C07K 16/32 (2006.01); G01N 33/569 (2006.01); A61K 31/517 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61N 5/10 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/32 (2013.01); A61K 31/517 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61N 5/10 (2013.01); C07K 16/2863 (2013.01); C07K 16/40 (2013.01); G01N 33/5695 (2013.01); G01N 33/57423 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/76 (2013.01); G01N 2333/4756 (2013.01);
Abstract

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low. The invention is also directed to methods of performing an ELISA, including sequential steps of contacting a solid surface with a plurality of solutions each comprising in turn a capture antibody, a blocking agent, a sample suspected of containing an analyte, a detection antibody and an enzyme conjugate, in which the solid surface is subjected to a wash process after each sequential step.


Find Patent Forward Citations

Loading…